Enzyme Engineering towards a Fully Biocatalytic Manufacturing Route for MK-8591

Conference Dates

September 15-19, 2019


With 37 million people around the world infected with HIV—and this number rising by almost 2 million a year—the search for newer, better medicines to treat this deadly disease remains an important goal. MK-8591 is a nucleoside reverse transcriptase inhibitor currently undergoing clinical trials for the treatment of HIV.

In order to achieve a world-class manufacturing route to this target that is also green and sustainable, the process chemistry team has turned to biocatalysis. Specifically, the 4’-ethynyl-2’-deoxyribose sugar portion of the molecule is prepared via a highly efficient three-enzyme cascade sequence. Another multi-enzyme reaction system is then used to append the 2-fluoroadenine base, overcoming a challenging glycosylation reaction.

This bold endeavor has posed numerous technical challenges in the optimization of complex multi-enzyme systems, the need for directed evolution of multiple enzymes, the detection and analysis of polar chromophore-free molecules and the isolation of unstable and highly water-soluble intermediates. An overview of the ongoing development and unique challenges—and opportunities—of this unprecedented fully-enzymatic manufacturing route will be presented.

This document is currently not available here.